Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report

Anna Piekarska; Aleksandra Berkan-Kawińska; Zbigniew Deroń; Justyna Ciupińska; Jolanta Białkowska

doi:10.5114/ceh.2020.93059

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020
vol. 6

Send email

Copy url:

abstract:

Report

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report

Anna Piekarska

¹

,

Aleksandra Berkan-Kawińska

¹

,

Zbigniew Deroń

²

,

Justyna Ciupińska

²

,

Jolanta Białkowska

¹

Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland
Department of Infectious Diseases and Liver Diseases, WSSz Bieganski, Lodz, Poland

Clin Exp HEPATOL 2020; 6, 1: 60–62

DOI: https://doi.org/10.5114/ceh.2020.93059

Online publish date: 2020/02/17

View full text Get citation

PlumX metrics:

Aim of the study
The aim of this overview was to evaluate the efficacy of sofosbuvir/velpatasvir (SOF/VEL) combination in a real-life setting, with particular regard to treatment-experienced individuals.

Material and methods
Seventy-five consecutive patients who were treated with SOF/VEL, completed the 12-week follow-up and had sustained virologic response (SVR) evaluated were included in the analysis. Out of them, 60 (80%) patients were treatment-naïve and 15 (20%) were treatment-experienced.

Results
SVR rates reached 89.4% (66/75) in the whole study group and were comparable irrespective of the fibrosis stage or HCV genotype. However, a significant difference in treatment efficacy between treatment-naïve and treatment-experienced individuals was observed, with SVR rates of 98.3% (59/60) and 46.7% (7/15), respectively (p < 0.0001).

Conclusions
Further studies including large real-life cohorts of treatment-experienced patients treated with SOF/VEL are warranted to elucidate the real efficacy of this regimen as a retreatment option.

keywords:

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report

Anna Piekarska 1 , Aleksandra Berkan-Kawińska 1 , Zbigniew Deroń 2 , Justyna Ciupińska 2 , Jolanta Białkowska 1

retreatment, chronic hepatitis C, velpatasvir/sofosbuvir

Anna Piekarska

¹

,

Aleksandra Berkan-Kawińska

¹

,

Zbigniew Deroń

²

,

Justyna Ciupińska

²

,

Jolanta Białkowska

¹